| __timestamp | Galapagos NV | Protagonist Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 111110000 | 7459000 |
| Thursday, January 1, 2015 | 129714000 | 11831000 |
| Friday, January 1, 2016 | 139574000 | 25705000 |
| Sunday, January 1, 2017 | 218502000 | 46181000 |
| Monday, January 1, 2018 | 322876000 | 59497000 |
| Tuesday, January 1, 2019 | 427320000 | 65003000 |
| Wednesday, January 1, 2020 | 523667000 | 74506000 |
| Friday, January 1, 2021 | 491707000 | 126006000 |
| Saturday, January 1, 2022 | 515083000 | 126215000 |
| Sunday, January 1, 2023 | 241294000 | 120161000 |
In pursuit of knowledge
In the ever-evolving landscape of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Galapagos NV and Protagonist Therapeutics, Inc. have demonstrated contrasting trajectories in their R&D investments. From 2014 to 2023, Galapagos NV consistently outpaced Protagonist Therapeutics, with its R&D expenses peaking in 2020 at over 500% of its 2014 levels. However, a notable decline occurred in 2023, with expenses dropping by more than 50% from the previous year. In contrast, Protagonist Therapeutics showed a steady increase, culminating in a 2022 peak that was over 1600% of its 2014 spending. This trend highlights Protagonist's growing focus on innovation, while Galapagos's recent dip may suggest a strategic shift or market adaptation. These insights offer a glimpse into the dynamic strategies of biotech firms in a competitive market.
Who Prioritizes Innovation? R&D Spending Compared for Biogen Inc. and Protagonist Therapeutics, Inc.
Comparing Innovation Spending: Neurocrine Biosciences, Inc. and Galapagos NV
Analyzing R&D Budgets: Intra-Cellular Therapies, Inc. vs Galapagos NV
Comparing Innovation Spending: Bio-Techne Corporation and Galapagos NV
R&D Insights: How Sarepta Therapeutics, Inc. and Galapagos NV Allocate Funds
Comparing Innovation Spending: Ascendis Pharma A/S and Protagonist Therapeutics, Inc.
Research and Development Investment: Madrigal Pharmaceuticals, Inc. vs Protagonist Therapeutics, Inc.
Grifols, S.A. vs Protagonist Therapeutics, Inc.: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for Xenon Pharmaceuticals Inc. and Galapagos NV
Research and Development Expenses Breakdown: Amicus Therapeutics, Inc. vs Protagonist Therapeutics, Inc.
Comparing Innovation Spending: Protagonist Therapeutics, Inc. and Agios Pharmaceuticals, Inc.
Galapagos NV vs Celldex Therapeutics, Inc.: Strategic Focus on R&D Spending